O. Toutirais

发表

Constitutive expression of TGF-bêta1, interleukin-6 and interleukin-8 by tumor cells as a major component of immune escape in human ovarian carcinoma.

F. Bouet, J. Levêque, D. Dubois, 2003, European cytokine network.

Tissue plasminogen activator worsens experimental autoimmune encephalomyelitis by complementary actions on lymphoid and myeloid cell responses

A. Miralles, D. Vivien, D. Clemente, 2020, Journal of neuroinflammation.

Low TCR avidity and lack of tumor cell recognition in CD8+ T cells primed with the CEA-analogue CAP1-6D peptide

P. Romero, G. Parmiani, L. Rivoltini, 2007, Cancer Immunology, Immunotherapy.

CRTAM Receptor Engagement by Necl-2 on Tumor Cells Triggers Cell Death of Activated Vγ9Vδ2 T Cells

J. Latouche, C. T. de La Pintière, O. Toutirais, 2013, The Journal of Immunology.

Immunostimulatory Properties of Dendritic Cells after Leishmania donovani Infection Using an In Vitro Model of Liver Microenvironment

C. Guguen-Guillouzo, A. Corlu, J. Gangneux, 2010, PLoS neglected tropical diseases.

Vγ9Vδ2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas

K. Boudjema, B. Meunier, O. Toutirais, 2008, Cancer Immunology, Immunotherapy.

HLA-Class II Artificial Antigen Presenting Cells in CD4+ T Cell-Based Immunotherapy

D. Vivien, J. Latouche, O. Boyer, 2019, Front. Immunol..

Ex vivo expansion of antitumor cytotoxic lymphocytes with tumor-associated antigen-loaded dendritic cells.

C. T. de La Pintière, O. Toutirais, V. Catros-Quemener, 2005, Anticancer research.

Cytotoxic effector cells with antitumor activity can be amplified ex vivo from biopsies or blood of patients with renal cell carcinoma for cell therapy use

N. Rioux-Leclercq, J. Patard, Anne-Sophie Thirouard, 2003, Cancer Immunology, Immunotherapy.

Aminobisphosphonate-pretreated dendritic cells trigger successful Vγ9Vδ2 T cell amplification for immunotherapy in advanced cancer patients

K. Boudjema, J. Mönkkönen, V. Lavoué, 2010, Cancer Immunology, Immunotherapy.

Artificial antigen‐presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4+ T cells

T. Frebourg, D. Vivien, J. Leprince, 2016, Immunology and cell biology.

Targeting NMDA Receptors at the Neurovascular Unit: Past and Future Treatments for Central Nervous System Diseases

D. Vivien, Fanny Potzeha, O. Toutirais, 2022, International journal of molecular sciences.

Activation of tumor‐specific T cells by dendritic cells expressing the NY‐ESO‐1 antigen after transfection with the cationic lipophosphoramide KLN5

P. Delépine, T. Montier, P. Lehn, 2008, The journal of gene medicine.

Soluble HLA‐G molecules impair natural killer/dendritic cell crosstalk via inhibition of dendritic cells

F. Gros, O. Toutirais, F. Cabillic, 2008, European journal of immunology.

CD49d expression as a promising biomarker to monitor natalizumab efficacy

G. Defer, N. Derache, O. Toutirais, 2012, Journal of the Neurological Sciences.

HLA-A*0201-restricted CEA-derived Peptide CAP1 Is Not a Suitable Target for T-cell-based Immunotherapy

H. Vaudry, T. Frebourg, J. Leprince, 2010, Journal of immunotherapy.

In vitro antitumor lymphocyte generation using dendritic cells and innate immunity mechanisms as tumor cell treatments.

C. T. de La Pintière, O. Toutirais, V. Catros-Quemener, 2007, Anticancer research.

Interleukin‐6 and vascular endothelial growth factor release by renal cell carcinoma cells impedes lymphocyte–dendritic cell cross‐talk

N. Rioux-Leclercq, J. Patard, P. Fergelot, 2006, Clinical and experimental immunology.

Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas.

K. Boudjema, B. Meunier, M. Le Gallo, 2008, Cancer immunology, immunotherapy : CII.

Effects of CD40 binding on ovarian carcinoma cell growth and cytokine production in vitro

J. Levêque, O Toutirais, A Gervais, 2007, Clinical and experimental immunology.

Roles of the tissue-type plasminogen activator in immune response

D. Vivien, D. Clemente, F. Docagne, 2021, Cellular Immunology.

Autoimmune encephalitis mediated by B-cell response against N-methyl-d-aspartate receptor.

O. Etard, M. Naveau, D. Vivien, 2020, Brain : a journal of neurology.

DNAX accessory molecule‐1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vγ9Vδ2 T cells

P. Loyer, F. Bouet, M. Le Gallo, 2009, European journal of immunology.

Increased frequencies of circulating and tumor-resident Vδ1+ T cells in patients with diffuse large B-cell lymphoma

M. Macro, X. Troussard, O. Reman, 2018, Leukemia & lymphoma.

Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients

A. Toubert, C. Deligne, P. Brice, 2019, Cancer Immunology, Immunotherapy.

Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring

G. Defer, B. Le Mauff, O. Toutirais, 2020, Frontiers in Immunology.

Stroke and the immune system: from pathophysiology to new therapeutic strategies

U. Dirnagl, C. Ali, D. Vivien, 2011, The Lancet Neurology.

[Mechanisms of radiation-induced lymphopenia and therapeutic impact].

J. Thariat, B. Le Mauff, O. Toutirais, 2020, Bulletin du cancer.

[Nectins and nectin-like receptors DNAM-1 and CRTAM: new ways for tumor escape].

O. Toutirais, V. Catros, A. Thédrez, 2014, Medecine sciences : M/S.

Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of Vγ9Vδ2 T cells impaired by the prostaglandin E2 immunosuppressive factor: Implications for immunotherapy

J. Bansard, V. Lavoué, J. Levêque, 2012, International journal of cancer.

The ADAMTS131239–1253 peptide is a dominant HLA-DR1-restricted CD4+ T-cell epitope

S. Kaveri, S. Lacroix-Desmazes, L. Galicier, 2017, Haematologica.